Drugmaker Aspen has offered to pay the UK’s National Health System £8 million to resolve competition concerns.
Ireland-based Jazz Pharma has acquired Virginia-based Cavion in a deal that values the clinical-stage biotech company at up to $312.5 million.
Avid Radiopharmaceuticals, a subsidiary of Eli Lilly, has taken the Alzheimer's Institute of America to court over its “malicious” prosecution of a patent infringement case.
Allergan has filed a motion asking for its “trade secrets” to be removed from evidence in a dispute over its wrinkle treatment, Botox.
Sandoz has confirmed that it plans to appeal against a decision that upheld the validity of two of Amgen’s patents for its arthritis treatment Enbrel, effectively blocking the launch of Sandoz’s biosimilar version.
The US Court of Appeals for the Federal Circuit last week affirmed two findings that Dr Reddy’s and Hospira had infringed Eli Lilly’s cancer drug Alimta.
Bayer is set to acquire the rest of BlueRock Therapeutics, in a deal that values the Massachusetts-based cell therapy company at $1 billion.
The NHS will receive a £250 million investment to develop a new National AI Lab, which will use the technology to improve patient health, the UK government has announced.
The US Federal Trade Commission is requiring medical device maker Boston Scientific to divest business, as part of a settlement resolving antitrust charges related to its acquisition of UK-based healthcare company BTG.
A subsidiary of Akebia Therapeutics has entered into a settlement agreement with Endo-owned Par Pharmaceutical.